Enanta Pharmaceuticals, Inc. (ENTA)

Over the past six months, Enanta announced positive Phase 2b results for zelicapavir, completed a public offering of common stock, reported financial results, and announced EPS-3903 as its lead STAT6 inhibitor candidate. They also provided updates on R&D programs, including plans for Phase 3 studies and IND filings. Enanta reported financial results for its fiscal first quarter, presented preclinical data for EDP-978, and announced presentations for its STAT6 inhibitor program. Oral arguments for Enanta's patent infringement case appeal against Pfizer are scheduled for May 11, 2026. The stock has increased by 18.53% over the last six months and 108.97% over the past year.

As a clinical-stage biopharmaceutical company, the demand for Enanta Pharmaceuticals' products and services is not subject to traditional consumer demand seasonality. The company's revenue is primarily derived from ongoing royalties from its partnered HCV drugs. Stock performance seasonality data suggests that February has been the strongest month for Enanta's stock, while May tends to be the weakest.

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing oral small molecule drugs for virology and immunology. Their pipeline includes HCV protease inhibitors, RSV treatments like Zelicapavir and EDP-323, HBV treatment EDP-514, human coronavirus treatment EDP-235, and immunology programs such as EDP-978 and EPS-3903.

Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts, with research and development operations in the U.S. Its partnered HCV products are commercialized globally by AbbVie.

Enanta Pharmaceuticals has maintained a reputation for scientific expertise and innovation, particularly in the discovery and development of small molecule drugs. A significant event impacting its reputation is the ongoing patent infringement lawsuit against Pfizer concerning Paxlovid, with Enanta appealing the initial unfavorable ruling.

Enanta Pharmaceuticals is predominantly owned by institutional shareholders, who hold 90.93% of the company's stock. Insiders own 49.04%, while retail investors hold 0.00%. Major institutional owners include Janus Henderson Group Plc, BlackRock, Inc., and Farallon Capital Management Llc. The largest individual shareholder is Helmut Schuhsler, who owns 5.76 million shares, representing 19.85% of the company.